Tris Pharma has enhanced its supply chain, increased manufacturing capacity, and added to its management team. Tris has received five new ANDA approvals from the FDA, and has several ANDAs and two NDAs pending approval. To accommodate these projects, Tris initiated the expansion of its manufacturing capacity earlier this year and is midway through the 15-month project that will expand the facility from 90,000 sq. ft. to approximately 200,000 sq. ft. The first phase doubles the company’s cGMP cap...